AstraZeneca Pares R&D Areas By 25 Percent
This article was originally published in The Pink Sheet Daily
Executive Summary
The Outsiders: Restructuring shows small biotechs' value in building Big Pharma's pipeline, says Targacept CEO Donald deBethizy.